Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.

about

Breast cancer medications and vision: effects of treatments for early-stage disease.Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.

P2860

Q35496778-D3BD8CD5-9251-46DA-B766-F4A4CE2F810E Q36924320-6E501A28-C9A6-48B5-BE13-13D9C68CFF58 Q37577926-72EB05D6-DCE0-4EF6-9FB2-44043D8905A9

P2860

Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.

Item

http://www.wikidata.org/entity/Q36950482

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Insights on adjuvant endocrine ...... postmenopausal breast cancer.

@en

type

Item

label

Insights on adjuvant endocrine ...... postmenopausal breast cancer.

@en

prefLabel

Insights on adjuvant endocrine ...... postmenopausal breast cancer.

@en

P1476

Insights on adjuvant endocrine ...... postmenopausal breast cancer.

@en

P2093

Antonio C Wolff

http://www.w3.org/2001/XMLSchema#string

Susanne Briest

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

P304

1243-1253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.7.9.1243

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17892424

http://www.w3.org/2001/XMLSchema#string

Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.

about

P2860

P2860

Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698